IP Library Granted Patent US 7,361,676
Granted Patent B2
US 7,361,676 · App. 10/503,391 · Granted Apr 22, 2008

Solid preparation containing single crystal form

Assignee: Teijin Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,361,676
App. No.
10/503,391
Granted
Apr 22, 2008
Kind
B2
Abstract

There are provided a solid preparation containing a single crystal of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, an excipient and a disintegrating agent, and a method for producing the same.

Claims (10)

1. A tablet comprising crystal A of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid with an X-ray powder diffraction pattern having specific peaks at a reflection angle 2θ, of 6.62°, 7.18°, 12.80°, 13.26°, 16.48°, 19.58°, 21.92°, 22.68°, 25.84°, 26.70°, 29.16° and 36.70°, an excipient, and a disintegrating agent, wherein the average particle diameter of the crystal A is from 12.9 μm to 26.2 μm.

2. The tablet according to claim 1 , wherein the tablet is prepared by a wet granulating method.

3. The tablet according to claim 1 or 2 , wherein said excipient is one or more selected from the group consisting of lactose and partly pregelatinized starch.

4. The tablet according to claim 1 or 2 , further comprising hydroxypropyl cellulose as a binder.

5. The tablet according to claim 1 or 2 , wherein the tablet is coated with polyethylene glycol.

6. A method for producing the tablet according to claim 2 comprising combining said crystal A of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid with an X-ray powder diffraction pattern having specific peaks at a reflection angle 2θ, of 6.62°, 7.18°, 12.80°, 13.26°, 16.48°, 19.58°, 21.92°, 22.68°, 25.84°, 26.70°, 29.16° and 36.70°, an excipient, and a disintegrating agent, wherein the average particle diameter of the crystal A is from 12.9 μm to 26.2 μm.

7. The method for producing a tablet according to claim 6 , comprising a step of wet granulating.

8. The method for producing a tablet according to claim 6 or 7 , wherein said excipient is one or more selected from the group consisting of lactose and partly pregelatinized starch.

9. The method for producing a tablet according to claim 6 or 7 , wherein hydroxypropyl cellulose is added as a binder.

10. The method for producing a tablet according to claim 6 or 7 , comprising a step of coating the tablet with polyethylene glycol.

Assignments (4)
CHANGE OF ADDRESS Recorded Jan 18, 2013
From: TEIJIN PHARMA LIMITED
To: TEIJIN PHARMA LIMITED
Reel/Frame 029660/0417 →
COPORATE SPLIT Recorded Jan 18, 2013
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 029660/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2005
From: TEIJIN LIMITED
To: TEIJIN PHARMA LIMITED
Reel/Frame 016406/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2004
From: IWAI, MICHIO; NAKAMURA, KAZUHIRO; DOHI, MASAHIKO; MOCHIZUKI, HIROKO; MOCHIZUKI, SEIJI
To: TEIJIN LIMITED
Reel/Frame 015944/0386 →
Priority Claims (1)
JP 2002-090889 · Mar 28, 2002 · national
Continuity (1)
Related Publication 20050043375A1 · Feb 24, 2005